Want to see AYTU full AI Analyst Report?
AYTU Stock Chart & Stats
$2.30
$0.00(0.00%)
At close: 4:00 PM EDT
$2.30
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$1.80 - $3.07
Previous Close$2.16
Volume10.41K
Average Volume (3M)40.78K
Market Cap
$21.41M
Enterprise Value$33.34M
Total Cash (Recent Filing)$26.31M
Total Debt (Recent Filing)$18.11M
Price to Earnings (P/E)―
Beta1.76
Next Earnings
Nov 16, 2026EPS Estimate
-0.26Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.16
Shares Outstanding10,866,708
10 Day Avg. Volume27,478
30 Day Avg. Volume40,781
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)0.75
Price to Sales (P/S)0.46
P/FCF Ratio8.14
Enterprise Value/Market Cap1.56
Enterprise Value/Revenue0.58
Enterprise Value/Gross Profit0.91
Enterprise Value/Ebitda-3.93
Forecast
1Y Price Target
$9.67Price Target Upside320.29% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.86
Revenue Forecast (FY)$67.86M
Bulls Say, Bears Say
Bulls Say
EXXUA Prescription And Revenue MomentumEXXUA is showing measurable commercial traction, with revenue and prescriptions rising substantially as the launch progresses. Continued prescription growth can broaden Aytu’s revenue base, improve operating leverage, and make the product an increasingly important contributor to the company’s future scale.
Deleveraging And Improved Cash GenerationThe shift to positive operating cash flow alongside debt repayment strengthens Aytu’s financial flexibility. Lower leverage and reduced interest obligations leave more resources available for commercialization, while a smaller debt burden improves resilience if product growth or quarterly cash generation fluctuates.
Durable ADHD Portfolio ContributionStrong prescription retention in the Adzenys franchise supports a defensible legacy revenue stream and reduces dependence on continuous promotional spending. This established portfolio can provide recurring profit and cash to help finance EXXUA expansion while newer commercial efforts mature.
Bears Say
Persistent Losses And Negative Adjusted EBITDAAytu has not yet converted its improved cash generation into sustained profitability, with full-year adjusted EBITDA and net income still negative. Until revenue scales sufficiently against operating costs, earnings conversion remains uncertain and the company remains exposed to execution risk.
Volatile And Declining Revenue BaseThe uneven revenue trajectory makes the business less predictable and complicates planning for sales, staffing, and investment. A sharp annual decline after prior expansion indicates that existing products have not yet established consistent growth, increasing the importance of successful EXXUA scaling.
Near-term Commercialization Cost And Cash-flow PressurePlanned EXXUA investment is expected to weigh on profitability and cash flow before the spending produces its full commercial benefit. This creates a near-term funding and execution challenge, particularly because seasonal factors and regulatory fees add pressure during the same period.
Aytu BioScience News
AYTU FAQ
What was Aytu BioScience Inc’s price range in the past 12 months?
Aytu BioScience Inc lowest stock price was $1.80 and its highest was $3.06 in the past 12 months.
What is Aytu BioScience Inc’s market cap?
Aytu BioScience Inc’s market cap is $21.41M.
When is Aytu BioScience Inc’s upcoming earnings report date?
Aytu BioScience Inc’s upcoming earnings report date is Nov 16, 2026 which is in 33 days.
How were Aytu BioScience Inc’s earnings last quarter?
Aytu BioScience Inc released its earnings results on Sep 22, 2026. The company reported $0 earnings per share for the quarter, beating the consensus estimate of -$0.29 by $0.29.
Is Aytu BioScience Inc overvalued?
According to Wall Street analysts Aytu BioScience Inc’s price is currently Undervalued.
Does Aytu BioScience Inc pay dividends?
Aytu BioScience Inc does not currently pay dividends.
What is Aytu BioScience Inc’s EPS estimate?
Aytu BioScience Inc’s EPS estimate is -0.26.
How many shares outstanding does Aytu BioScience Inc have?
Aytu BioScience Inc has 10,866,708 shares outstanding.
What happened to Aytu BioScience Inc’s price movement after its last earnings report?
Aytu BioScience Inc reported an EPS of $0 in its last earnings report, beating expectations of -$0.29. Following the earnings report the stock price went up 2.242%.
Which hedge fund is a major shareholder of Aytu BioScience Inc?
Currently, no hedge funds are holding shares in AYTU
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Aytu BioScience Inc
Aytu BioPharma, Inc. is a specialized pharmaceutical firm dedicated to advancing and marketing innovative therapeutic drugs and consumer health products, serving both domestic U.S. and international markets. Its commercialized portfolio includes several treatments for Attention Deficit Hyperactivity Disorder (ADHD): Adzenys XR-ODT, prescribed for patients aged 6 and up; Cotempla XR-ODT, tailored for individuals between 6 and 17 years old; and Adzenys ER, an oral liquid formulation also for those 6 years and older. Additionally, the company offers Karbinal ER, an oral carbinoxamine suspension for managing seasonal and perennial allergies. It also provides Poly-Vi-Flor and Tri-Vi-Flor, which are prescription vitamin supplements designed for infants and children with fluoride deficiencies. Other products include Tuzistra XR, a prescription cough suppressant oral suspension containing codeine polistirex and chlorpheniramine polistirex, and ZolpiMist, an oral spray indicated for addressing insomnia. Founded in 2015, the company was previously known as Aytu BioScience, Inc. before officially changing its name to Aytu BioPharma, Inc. in March 2021. Its corporate headquarters are located in Englewood, Colorado.
AYTU Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call was strongly optimistic, centered on EXXUA's accelerating prescriptions, broadening prescriber and patient adoption, favorable access and gross-to-net performance, and a return to positive fourth-quarter adjusted EBITDA. The company also highlighted resilient legacy products, improved operating cash generation, and debt reduction. Challenges included the early stage of the EXXUA launch, temporary sales-force coverage reductions, year-over-year declines in ADHD and pediatrics revenue, lower gross margin versus the prior year, and expected first-half fiscal 2027 profitability and cash-flow softness. Highlights significantly outweighed the lowlights.View all AYTU earnings summariesAYTU Stock 12 Month Forecast
Average Price Target
$9.67
▲(320.29% Upside)
Technical Analysis
Sonoma Pharmaceuticals
―
TherapeuticsMD
―
RedHill Biopharma
―
Cumberland Pharmaceuticals
―
Eton Pharmaceuticals
―
Ownership Overview
5.14% Insiders
3.37% Mutual Funds
65.51% Other Institutional Investors
23.42% Public Companies and
Individual Investors